Lantheus

LNTHNasdaq United States Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$6.546 B

$100.28 -0.27%

Close of 21 Sept 2026

Revenue

$1.54B

#1279 by revenue

Earnings

$233.6M

#936 by earnings

Shares outstanding

65,272,369

Latest filing cover page

P/E ratio

28.0

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances, ranked by market cap

All 19 →

#1Idexx LaboratoriesIDXX$40.6B
#2LantheusLNTH$6.55B
#3Oruka TherapeuticsORKA$6.18B
#4Celldex TherapeuticsCLDX$2.98B
#5NeogenNEOG$2.97B

What if Lantheus were worth as much as…

Open the what-if tool →

Gold $30.3T

$463,811.17

Per share 4,625× higher

Bitcoin $1.72T

$26,348.11

Per share 263× higher

Nvidia $5.48T

$83,953.72

Per share 837× higher

Or at a round number

$10.0B $20.0B $50.0B $100.0B

Where these numbers come from

Share counts and financials for Lantheus are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.